Production of Therapeutic Levels of Human FIX-R338L by Engineered B Cells Using GMP-Compatible Medium

Researchers established an advanced in vitro good manufacturing practice-compatible culturing system characterized by robust and consistent expansion rate, high viability, and efficient B cell differentiation.